Abstract
A high circulating level of homocysteine (Hcy), also known as hyperhomocysteinemia, is a risk factor for Alzheimer’s disease (AD). Previous studies show that elevated Hcy promotes brain amyloidosis and behavioral deficits in mouse models of AD. However, whether it directly modulates the development of tau neuropathology independently of amyloid beta in vivo is unknown. Herein, we investigate the effect of diet-induced elevated levels of brain Hcy on the phenotype of a relevant mouse model of human tauopathy. Compared with controls, tau mice fed with low folate and B vitamins diet had a significant increase in brain Hcy levels and worsening of behavioral deficits. The same mice had a significant elevation of tau phosphorylation, synaptic pathology, and astrocytes activation. In vitro studies demonstrated that Hcy effect on tau phosphorylation was mediated by an upregulation of 5-lipoxygenase via cdk5 kinase pathway activation. Our findings support the novel concept that high Hcy level in the central nervous system is a metabolic risk factor for neurodegenerative diseases, specifically characterized by the progressive accumulation of tau pathology, namely tauopathies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2016;12:459–9.
Giannopoulos PG, Praticò D. Alzheimer’s disease. In: Colin RM, Victor, R, editors. Diet and Nutrition in Dementia and Cognitive Decline. London: Elsevier Publisher; 2005. p. 13–21.
Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126(Pt 3):238–92.
Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609–22.
Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr. 2016;36:211–39.
Shen L, Ji HF. Associations between homocysteine, folic Acid, vitamin B12 and Alzheimer’s disease: insights from meta-analyses. J Alzheimers Dis. 2015;46:777–90.
Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Praticò D. Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2010;7:140–9.
Fuso A, Nicolia V, Ricceri L, Cavallaro RA, Isopi E, Mangia F, et al. S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice. Neurobiol Aging. 2012;33:1482.e1–16.
Zhuo JM, Praticò D. Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer’s disease. FASEB J. 2010;24:3895–902.
Suszyńska-Zajczyk J, Luczak M, Marczak L, Jakubowski H. Hyperhomocysteinemia and bleomycin hydrolase modulate the expression of mouse brain proteins involved in neurodegeneration. J Alzheimers Dis. 2014;40:713–26.
Li JG, Barrero C, Merali S, Praticò D. Homocysteine modulates 5-lipoxygenase expression level via DNA methylation. Aging Cell. 2017;16:273–80.
Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582–90.
Li JG, Chu J, Barrero C, Merali S, Praticò D. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol. 2014;75:851–63.
Di Meco A, Lauretti E, Vagnozzi AN, Praticò D. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer’s disease mice. Neurobiol Aging. 2014;35:2458–64.
Giannopoulos PF, Chu J, Sperow M, Li JG, Yu WH, Kirby LG, et al. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer’s disease. Mol Psychiatry. 2014;19:511–8.
Vagnozzi AN, Giannopoulos PF, Praticò D. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Transl Psychiatry. 2017;7:1288.
Giannopoulos PF, Chu J, Sperow M, Li JG, Yu WH, Kirby LG, et al. Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry. 2015;78:693–701.
Moncada CA, Clarkson A, Perez-Leal O, Merali S. Mechanism and tissue specificity of nicotine-mediated lung S-adenosylmethionine reduction. J Biol Chem. 2008;283:7690–6.
Joshi YB, Giannopoulos PF, Chu J, Sperow M, Kirby LG, Abood ME, et al. Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer’s disease. Hum Mol Genet. 2014;23:6894–902.
Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D. 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol. 2012;72:442–54.
Chu J, Praticò D. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer’s disease transgenic mouse model involvement of γ-secretase. Am J Pathol. 2011;178:1762–9.
Chu J, Praticò D. 5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol Aging. 2013;34:1549–54.
McCully KS. Homocysteine metabolism, atherosclerosis, and diseases of aging. Compr Physiol. 2015;6:471–505.
Miwa K, Tanaka M, Okazaki S, Yagita Y, Sakaguchi M, Mochizuki H, et al. Increased total homocysteine levels predict the risk of incident dementia independent of cerebral small-vessel diseases and vascular risk factors. J Alzheimers Dis. 2016;49:503–13.
Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300:1774–83.
Pratico D. High-dose B vitamin supplements and Alzheimer disease. JAMA. 2009;301:1020–1.
Zhuo JM, Wang H, Praticò D. Is hyperhomocysteinemia an Alzheimer’s disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci. 2011;32:562–71.
Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, et al. Hyperhomocysteinemic Alzheimer’s mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis. 2006;22:651–6.
Chung YC, Kruyer A, Yao Y, Feierman E, Richards A, Strickland S, et al. Hyperhomocysteinemia exacerbates Alzheimer’s disease pathology by way of the β-amyloid fibrinogen interaction. J Thromb Haemost. 2016;14:1442–52.
Li JG, Praticò D. High levels of homocysteine results in cerebral amyloid angiopathy in mice. J Alzheimers Dis. 2015;43:29–35.
Li JG, Merali S, Pratico D. Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype. Sci Rep. 2017;6:7. 46002
Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29:10741–9.
Li JG, Barrero C, Merali S, Praticò D. Genetic absence of ALOX5 protects from homocysteine-induced memory impairment, tau phosphorylation and synaptic pathology. Hum Mol Genet. 2017;26:1855–62.
Acknowledgements
Domenico Praticò is the Scott Richards North Star Charitable Foundation Chair for Alzheime'rs research. The work presented in this paper was in part supported by grants from the National Institute of Health (HL112966 and AG51684).
Author contributions:
ADM and DP designed the study; ADM and JGL performed the experiments; CB and SM were involved in the measurement of Hcy SAM an SAH; ADM and DP analyzed the data and drafted the manuscript. All authors have discussed the results and seen the final version of the paper before submission.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Di Meco, A., Li, JG., Barrero, C. et al. Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy. Mol Psychiatry 24, 1696–1706 (2019). https://doi.org/10.1038/s41380-018-0062-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-018-0062-0
This article is cited by
-
Differential expression of m5C RNA methyltransferase genes NSUN6 and NSUN7 in Alzheimer’s disease and traumatic brain injury
Molecular Neurobiology (2023)
-
Rivastigmine Reverses the Decrease in Synapsin and Memory Caused by Homocysteine: Is There Relation to Inflammation?
Molecular Neurobiology (2022)
-
Homocysteine and Gliotoxicity
Neurotoxicity Research (2021)
-
Blood total antioxidant status is associated with cortical glucose uptake and factors related to accelerated aging
Brain Structure and Function (2020)